Clinical Trial Update: TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd [Phase 2]

View source ↗

Summary

A Phase 2 trial (TRADE DXd) evaluating two antibody-drug conjugates, Dato-DXd and T-DXd, for ADC-refractory breast cancer including HER2-low and HER2-negative m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low Breast Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• T-DXd (trastuzumab deruxtecan)

Snippet

Sponsor: Ana C Garrido-Castro, MD | Conditions: Breast Cancer, HER2-low Breast Cancer | Phase 2 | Status: RECRUITING